Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Retina. 2014 Sep;34(9):1779–1786. doi: 10.1097/IAE.0000000000000178

Fig. 1.

Fig. 1

Medical records of all patients tested for 25-hydroxyvitamin D (25OHD) and diagnosed by ICD-9 code for AMD were reviewed. Patients were included in the NNVAMD group if recommended AREDS supplementation and with NVAMD if patient had choroidal neovascularization in any eye not attributable to an alternate cause; patients whose 25OHD level was tested by LC-MS/MS assay were included in a separate analysis. The control group was selected from patients diagnosed with pseudophakia and tested for 25OHD level. A total of 226 medical records at random were reviewed, of which a control group was selected to match the NNVAMD group for sex, race, and age.